Bladder cancer market to reach $16 billion in 8MM in 2033
The bladder cancer market across the eight major markets (8MM: USA, France, Germany, Italy, Spain, UK, China, and Japan) is projected to grow from $3 billion in 2023 to $16 billion in 2033, at a compound annual growth rate (CAGR) of 18%.
The growth will be driven an increasing incidence of bladder cancer and a wave of therapeutic innovation across both non-muscle-invasive (NMIBC) and muscle-invasive bladder cancer (MIBC) segments, says pharma analytics company GlobalData.
GlobalData’s recent report, “Bladder Cancer: Eight-Market Drug Forecast and Market Analysis” reveals that the approval of novel intravesical therapies in NMIBC and antibody drug conjugates in MIBC is transforming the market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze